EDSA (Edesa Biotech) EPS (Basic): $-1.34 (TTM As of Mar. 2026)


EDSA Edesa Biotech Inc EDSA
26 GF Score
Price $7.95
! 2 Warning Signs
View Full Analysis

What is Edesa Biotech EPS (Basic)?

Edesa Biotech EDSA +5.58% 26 EPS (Basic) is $-1.34 as of Mar. 2026. GuruFocus rates EDSA with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

Edesa Biotech's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was $-0.49. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.34.

Edesa Biotech's EPS (Diluted) for the three months ended in Mar. 2026 was $-0.49. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.34.

Edesa Biotech's EPS without NRI for the three months ended in Mar. 2026 was $-0.49. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -1.34.

During the past 3 years, the average EPS without NRI Growth Rate was 46.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 29.60% per year. During the past 10 years, the average EPS without NRI Growth Rate was 40.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Edesa Biotech's highest 3-Year average EPS without NRI Growth Rate was 71.40% per year. The lowest was -94.60% per year. And the median was 22.05% per year.

Edesa Biotech  (NAS:EDSA) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Edesa Biotech EPS (Basic) Related Terms

Edesa Biotech EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Edesa Biotech's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edesa Biotech EPS (Basic) Chart

Edesa Biotech Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.70 -8.37 -2.93 -1.93 -1.27

Edesa Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.30 -0.25 -0.32 -0.28 -0.49
EDSA
26GF Score
Edesa Biotech Inc EDSA
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Edesa Biotech EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Edesa Biotech's Basic EPS for the fiscal year that ended in Sep. 2025 is calculated as

Basic EPS (A: Sep. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-7.186-0)/5.677
=-1.27

Edesa Biotech's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-4.218-0)/8.541
=-0.49

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $-1.34 mean?
Edesa Biotech (EDSA) has a EPS (Basic) of $-1.34 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Edesa Biotech and its competitors.
Is Edesa Biotech's EPS (Basic) too high?
Edesa Biotech's current EPS (Basic) is $-1.34. Overall, Edesa Biotech has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Edesa Biotech's EPS (Basic) compare to PMVP and IMA?
Edesa Biotech's EPS (Basic) of $-1.34 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Edesa Biotech and its competitors. Edesa Biotech's current EPS (Basic) is $-1.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edesa Biotech stock overvalued right now?
Edesa Biotech (EDSA) has a current EPS (Basic) of $-1.34. The current EPS (Basic) is $-1.34. Edesa Biotech's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Edesa Biotech (EDSA), the current EPS (Basic) is $-1.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Edesa Biotech Business Description

Address 100 Spy Court, Markham, ON, CAN, L3R 5H6
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
26GF Score

Get the complete analysis for EDSA

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.95
Price